No Prescription |
 |
 | ||
|
Emetil Largactil |
|
| ||
No Prescription » Prescription Drugs 7 » Emetil Largactil This medication is used to treat several mental/mood disorders (e.g. schizophrenia mania restlessness/nervousness behavior problems) nausea/vomiting hiccups and a certain liver problem (acute porphyria). For nervousness it is generally used when other medications cannot be taken. Chlorpromazine can improve the symptoms of schizophrenia mania and mood making it easier to function in everyday life. Chlorpromazine is part of a class of drugs called phenothiazines. It works by affecting the balance of certain chemicals in the brain. Buy Emetil Largactil and other Prescription Drugs 7 products online at Medstore. Buy Online at Medstore - Click Here!
About Emetil Largactil: Product Type: Prescription Drugs 7 Emetil (Largactil Generic Chlorpromazine) Emetil (Largactil Generic Chlorpromazine) Largactil Generic Chlorpromazine 100mg 100 Tablets 100mg 200(2 x 100) Tablets 100mg 400(4 x 100) Tablets 25mg 100 Tablets 25mg 200(2 x 100) Tablets 25mg 400(4 x 100) Tablets 50mg 100 Tablets 50mg 200(2 x 100) Tablets 50mg 400(4 x 100) Tablets Largactil Generic Chlorpromazine Emetil
View more Prescription Drugs 7 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
